 |
SV Life Sciences Fund III (SVLSFIII)SVLSF III closed in 2003 with total commitments of $393.2 million (plus $8.5 million of co-investments committed by partners and individuals affiliated with SVLS). As at 31 December 2006 the Fund had invested $242million in 38 portfolio companies. To go to individual portfolio companies websites please click
on company logo. 
Alba Therapeutics: USFirst investment: 2005 - Early Stage For the treatment of inflammatory and immune mediated diseases. Alinea: US First investment: 2005 - Expansion Alinea is a spinout that will develop a PTP1b inhibitor for insulin resistance. 
Archemix: USFirst investment: 2002 - Early Stage Develops aptamers as a new class of direct therapeutics for the prevention and treatment of chronic and acute disease. 
Avera Pharmaceuticals: USFirst investment: 2004 - Early Stage Development and commercialization of novel pharmaceutical compounds for treatment of neurologic and psychiatric disorders. 
Dynogen Pharmaceuticals: USFirst investment: 2004 - Early Stage Genito-urinary and gastro-intestinal disorders using neuroscience-based pharmaceutical drugs. 
ESBATech: SwitzerlandFirst investment: 2006 - Early Stage ESBATech is a preclinical stage drug discovery company exploiting a novel platform for antibody fragment discovery.  Fundamental Applied Biology, Inc.: US First investment: 2006 - Early Stage Fundamental Applied Biology (FAB), Inc. mission is enable the production of low-cost, high quality rapidly developed products and technology for protein pharmaceuticals and innovative vaccines. 
GlycoFi: USFirst investment: 2002 - Start Up - Exited Production and engineering of therapeutics proteins. 
Intranasal Therapeutics: USFirst investment: 2006 - Early Stage Intranasal Therapeutics, Inc. ("ITI") is a specialty pharmaceutical company focused on developing innovative, nasally delivered pharmaceutical products with a particular focus on drugs treating pain and CNS-related disorders. 
Lorantis: UKFirst investment SVLSF II: 2000 - Start Up First investment SVLSF III: 2003 - Early Stage Immunology based drugs. 
Lux Bioscience: USFirst investment: 2006 - Seed Opthalmic drugs 
Mpex Pharmaceuticals: USFirst investment: 2005 - Early Stage Development of new anti-bacterial drugs that meet the growing clinical need created by multi-drug resistant bacterial pathogens. 
Neurotech: USFirst investment: 2006 - Early Stage Neurotech is a biotechnology company dedicated to the development of sight-saving therapeutics for chronic retinal diseases. 
PowderMed: UKFirst investment: 2004 - Early Stage - Exited Development of therapeutic DNA vaccines in the areas of chronic viral diseases and cancer. 
Rinat Neuroscience: USFirst investment: 2003 - Early Stage - Exited Developing proteins for the treatment of diseases and disorders of the nervous system. 
Sapphire Therapeutics: USFirst investment: 2004 - Early Stage Developing compounds for treatment of oncologic and metabolic diseases. (Formerly known as Rejuvenon). 
|
